Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus

Immunotherapy. 2017 Jan;9(1):57-70. doi: 10.2217/imt-2016-0090.

Abstract

Dysregulation of the type I interferon (IFN) system is associated with various immunologic diseases, such as systemic lupus erythematosus (SLE). Targeting this dysregulation presents an attractive approach for SLE therapy. Sifalimumab, a fully human immunoglobulin G1 κ monoclonal antibody that binds to and neutralizes most IFN-α subtypes, has been recently evaluated in a Phase IIb study in patients with moderate to severe SLE. Insights gained from earlier studies were used to inform design of the Phase IIb study, to provide a more comprehensive evaluation of sifalimumab. Sifalimumab demonstrated broad efficacy across composite and organ-specific end points, suggesting that targeting of IFN-α is a promising treatment option for SLE, particularly for those patients whose disease is refractory to current standard of care.

Keywords: sifalimumab; systemic lupus erythematosus; type I interferon.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy / methods*
  • Interferon Type I / metabolism
  • Lupus Erythematosus, Systemic / drug therapy*
  • Molecular Targeted Therapy
  • Recurrence
  • Signal Transduction

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interferon Type I
  • sifalimumab